Doctor Care Anywhere posts H1 revenue of £20.4M
Doctor Care Anywhere (ASX:DOC) reported total revenue of £20.4 million for the six months ended June 30.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Doctor Care Anywhere (ASX:DOC) reported total revenue of £20.4 million for the six months ended June 30.
OncoSil Medical (ASX:OSL) secured U.S. FDA approval for its OncoSil device to treat distal cholangiocarcinoma, targeting an $80 million market.
Australian Clinical Labs (ASX:ACL) reported an underlying net profit of $35.5 million for the 2026 financial year.
Proteomics International (ASX:PIQ) received a notice of acceptance from IP Australia for a patent covering its PromarkerEndo blood test.
Alterity Therapeutics (ASX:ATH) secured a new U.S. composition of matter patent for its lead drug asset, ATH434.
Pro Medicus (ASX:PME) secured a seven-year, $23 million contract with St Luke's Health System to deploy its Visage 7 platform.
Anteris Technologies (ASX:AVR) reported financial results for the quarter ended June 30, alongside operational updates for its clinical trials.
TruScreen Group (ASX:TRU) appointed new distributors across Nigeria, Ghana, Côte d'Ivoire, and Rwanda to support public cancer screening programmes.
Starpharma (ASX:SPL) completed a fully underwritten entitlement offer to raise $32 million in new capital before costs.
Nanoveu (ASX:NVU) announced that it entered into a binding agreement with One Immersive to launch glasses-free 3D mobile films across India.
Helia Group (ASX:HLI) reported a 25% drop in first-half statutory net profit after tax to $100 million from $133.7 million.
ReNerve (ASX:RNV) secured marketing approval from India’s Central Drugs Standard Control Organisation for its NervAlign Nerve Cuff.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade